<DOC>
	<DOCNO>NCT01584115</DOCNO>
	<brief_summary>This study clinical trial phase I/II . Its goal determine safety , tolerability , immunogenicity efficacy therapeutic vaccine tumor antigen NY-ESO-1 combine adjuvant MPLA B. pertussis cancer patient .</brief_summary>
	<brief_title>Clinical Trial Therapeutic Vaccine With NY-ESO-1 Combination With Adjuvant Monophosphoryl Lipid A ( MPLA )</brief_title>
	<detailed_description>The safety immunogenicity vaccine antigen NY-ESO-1 combination MPLA evaluate phase 1 clinical trial conduct patient malignancy express antigen ( lung , ovarian melanoma ) . This study involve 15 patient , receive 250 mcg NY-ESO-1 100 mcg MPLA .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Monophosphoryl lipid A</mesh_term>
	<criteria>In study , include fifteen patient age 18 year , confirm diagnosis malignant neoplasm , proven NYESO1 expression immunohistochemistry undergone standard treatment . Will exclude study patient continuous use systemic steroid , immunosuppressive agent antibiotic , severe chronic systemic disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Cancer .</keyword>
	<keyword>Melanoma .</keyword>
	<keyword>Ovarian cancer .</keyword>
	<keyword>Lung cancer .</keyword>
	<keyword>NY-ESO-1 .</keyword>
	<keyword>MPLA ( monophosphoryl lipid A ) .</keyword>
	<keyword>Tumor antigen .</keyword>
	<keyword>Bordetella pertussis .</keyword>
</DOC>